ZYXI:NSD-Zynex Inc (USD)

COMMON STOCK | Medical Distribution |

Last Closing

USD 8.26

Change

+0.27 (+3.38)%

Market Cap

N/A

Volume

0.06M

Analyst Target

USD 27.35
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap
HSIC Henry Schein Inc

+1.03 (+1.48%)

USD 9.02B
PDCO Patterson Companies Inc

+0.38 (+1.80%)

USD 1.96B
AHG Akso Health Group ADR

+0.08 (+7.46%)

USD 0.25B
EDAP EDAP TMS SA

-0.05 (-1.71%)

USD 0.11B
YI 111 Inc

+0.06 (+9.87%)

USD 0.05B
COSM Cosmos Health Inc.

-0.05 (-4.93%)

N/A

ETFs Containing ZYXI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.15% 71% C- 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.15% 57% F 29% F
Trailing 12 Months  
Capital Gain 0.12% 86% B+ 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.12% 86% B+ 42% F
Trailing 5 Years  
Capital Gain -13.14% 67% D+ 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.14% 67% D+ 37% F
Average Annual (5 Year Horizon)  
Capital Gain 1.76% 43% F 47% F
Dividend Return 1.76% 43% F 43% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.33% 71% C- 41% F
Risk Adjusted Return 4.07% 43% F 41% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.